RAPT Therapeutics Inc (RAPT) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
RAPT Therapeutics Inc stock (RAPT) is currently trading at $58.02. RAPT Therapeutics Inc PS ratio (Price-to-Sales) is 411.22. Analyst consensus price target for RAPT is $58.00. WallStSmart rates RAPT as Sell.
- RAPT PE ratio analysis and historical PE chart
- RAPT PS ratio (Price-to-Sales) history and trend
- RAPT intrinsic value — DCF, Graham Number, EPV models
- RAPT stock price prediction 2025 2026 2027 2028 2029 2030
- RAPT fair value vs current price
- RAPT insider transactions and insider buying
- Is RAPT undervalued or overvalued?
- RAPT Therapeutics Inc financial analysis — revenue, earnings, cash flow
- RAPT Piotroski F-Score and Altman Z-Score
- RAPT analyst price target and Smart Rating
RAPT Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
RAPT Therapeutics Inc (RAPT) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around return on equity and price/sales. Significant fundamental concerns warrant caution or avoidance.
RAPT Therapeutics Inc (RAPT) Key Strengths (1)
110.57% of shares held by major funds and institutions
Supporting Valuation Data
RAPT Therapeutics Inc (RAPT) Areas to Watch (5)
Company is destroying shareholder value
Revenue declining -100.00%, a shrinking business
Very expensive at 411.2x annual revenue
Very expensive at 11.1x book value
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
RAPT Therapeutics Inc (RAPT) Detailed Analysis Report
Overall Assessment
This company scores 16/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 1 register as strengths (avg 10.0/10) while 5 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are Return on Equity, Revenue Growth, Price/Sales. Some valuation metrics including Price/Sales (411.22), Price/Book (11.05) suggest expensive pricing. Growth concerns include Revenue Growth at -100.00%, which may limit upside. Profitability pressure is visible in Return on Equity at -85.40%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -85.40% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -100.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Revenue Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
RAPT Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
RAPT's Price-to-Sales ratio of 411.22x trades at a 27% premium to its historical average of 324.8x (66th percentile). The current valuation is 70% below its historical high of 1371.83x set in Jan 2020, and 2368% above its historical low of 16.66x in Apr 2025. Over the past 12 months, the PS ratio has expanded from ~23.1x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for RAPT Therapeutics Inc (RAPT) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
RAPT Therapeutics Inc operates as a stable business with moderate growth and solid fundamentals. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Debt-to-equity ratio of 0.02 indicates a conservative balance sheet with 38M in cash.
Revenue contracted 100% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -12M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact RAPT Therapeutics Inc.
Bottom Line
RAPT Therapeutics Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About RAPT Therapeutics Inc(RAPT)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. The company is headquartered in South San Francisco, California.